# Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

> **NCT06208657** · PHASE1,PHASE2 · RECRUITING · sponsor: **Australian & New Zealand Children's Haematology/Oncology Group** · enrollment: 90 (estimated)

## Conditions studied

- Childhood Cancer
- Childhood Solid Tumor
- Childhood Brain Tumor
- Recurrent Cancer
- Refractory Cancer

## Interventions

- **DRUG:** Paxalisib
- **DRUG:** Opdualag
- **DRUG:** Irinotecan (drug)
- **DRUG:** Temozolomide (TMZ)

## Key facts

- **NCT ID:** NCT06208657
- **Lead sponsor:** Australian & New Zealand Children's Haematology/Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-10
- **Primary completion:** 2030-12
- **Final completion:** 2035-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06208657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06208657, "Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06208657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*